OverviewSuggest Edit

Recro Gainesville (also known as Recro Pharma) is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The сompany is engaged in developing products for hospitals and ambulatory care settings that are developing non-opioid products for the treatment of serious acute pain. The сompany's lead product candidate is an injectable form of meloxicam.

TypePublic
Founded2006
HQGainesville, GA, US
Websiterecrogainesville.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2019)213(-16%)
Job Openings15
Revenue (FY, 2020)$66.5 M(-32%)
Share Price (Sept 2021)$2.1(+5%)
Cybersecurity ratingAMore

Key People/Management at Recro Gainesville

Wayne B. Weisman

Wayne B. Weisman

Chairman of the Board
David Smithwick

David Smithwick

Senior Vice President and Site Head
Ryan D. Lake

Ryan D. Lake

CFO
Shazib Jamil

Shazib Jamil

Senior Vice President and Site Head
William L. Ashton

William L. Ashton

Director
Michael Berelowitz

Michael Berelowitz

Director
Show more

Recro Gainesville Office Locations

Recro Gainesville has an office in Gainesville
Gainesville, GA, US (HQ)
1300 Gould Dr
Gainesville, GA, US
988 Chestnut St SE
Show all (2)

Recro Gainesville Financials and Metrics

Recro Gainesville Revenue

Recro Gainesville's revenue was reported to be $66.5 m in FY, 2020
USD

Net income (Q2, 2021)

1.2m

Market capitalization (23-Sept-2021)

94.6m

Closing stock price (23-Sept-2021)

2.1
Recro Gainesville's current market capitalization is $94.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

52.0m69.3m71.8m77.3m99.2m66.5m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m43.2m51.0m54.1m

Gross profit

23.9m32.2m33.6m34.2m48.2m12.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m17.1m19.5m21.7m18.3m25.1m31.3m25.3m21.8m15.5m16.8m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m6.9m10.5m12.1m8.5m14.4m14.1m11.0m18.3m11.6m14.3m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m10.2m9.1m9.7m9.8m10.7m17.2m14.2m3.5m3.9m2.5m

Gross profit Margin, %

50%39%42%45%66%44%38%60%46%44%54%43%55%56%16%25%15%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

19.7m19.8m64.5m61.0m38.5m19.1m23.8m

Accounts Receivable

89.6k8.6m10.4m9.7m12.9m14.4m9.0m

Prepaid Expenses

3.3m3.9m2.7m2.3m

Inventories

9.0m1.1m9.8m10.7m15.1m11.6m
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.1m)3.0m(30.2m)(50.1m)(79.7m)(18.6m)(27.5m)

Depreciation and Amortization

1.4k4.1m5.0m7.4m7.9m8.4m8.5m

Inventories

1.3m(325.0k)(1.1m)(860.0k)(4.4m)3.5m

Accounts Payable

1.1m2.2m8.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(26.0m)(12.5m)(25.2m)(38.4m)(2.0m)(4.8m)(9.1m)(7.7m)(13.7m)(6.8m)(5.5m)

Depreciation and Amortization

1.9m4.0m1.9m3.8m5.7m1.8m3.7m5.6m1.9m3.8m5.8m2.1m4.3m6.6m2.1m4.3m1.4m3.0m

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(1.1m)(189.0k)1.7m(343.0k)531.0k1.1m(2.2m)3.0m3.3m3.0m3.7m

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Recro Gainesville Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Gainesville Revenue Breakdown

Embed Graph

Recro Gainesville revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Recro Gainesville Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Recro Gainesville Online and Social Media Presence

Embed Graph

Recro Gainesville News and Updates

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Recro Pharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 2, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Recro Pharma, Inc. (NASDAQ: REPH). If you are a...

Recro Pharma Reports Third Quarter 2019 Financial Results

CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million

Recro Pharma Reports First Quarter 2019 Financial Results

Company to Host Conference Call Today at 8:00 AM ET Company to Host Conference Call Today at 8:00 AM ET

Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

Management to Host Conference Call and Webcast Today at 4:30 p.m. ET Management to Host Conference Call and Webcast Today at 4:30 p.m. ET

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam

Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years
Show more

Recro Gainesville Blogs

How to Select the Right Polymers for Your Modified Release Multiparticulate Capsule

I previously wrote a blog post about polymer selection for modified release tablets. This post will address the same considerations,... The post How to Select the Right Polymers for Your Modified Release Multiparticulate Capsule appeared first on Recro.

How to Maintain Accuracy, Consistency, and On-Time Delivery in the QC Lab

You have to rely on QC lab data to guide critical decisions, but flaws in project approaches, techniques, methods, and... The post How to Maintain Accuracy, Consistency, and On-Time Delivery in the QC Lab appeared first on Recro.

How to Select the Right Polymers for Your Modified Release Tablet

Many clients come to us with formulations they want to tech transfer or scale up and take into clinical studies.... The post How to Select the Right Polymers for Your Modified Release Tablet appeared first on Recro.

No More Missed Milestones: The Benefits of Clinical Trial Materials and Clinical Trial Supplies Consolidation

Increased competition, advanced technology, and the need to operate as efficiently as possible have prompted pharmaceutical companies of all sizes... The post No More Missed Milestones: The Benefits of Clinical Trial Materials and Clinical Trial Supplies Consolidation appeared first on Recro.

Careful and Proactive Planning of Packaging and Distribution Strategy Saves Time and Cost

Once a clinical trial is in progress, a variety of causes, such as fluctuating enrollment or emerging clinical safety or... The post Careful and Proactive Planning of Packaging and Distribution Strategy Saves Time and Cost appeared first on Recro.

3 Examples of Multiparticulates Enabling Performance a Matrix Tablet Can’t

For Modified (Controlled) Release Oral Solid Dosage Forms In modified release oral solid dosage forms, matrix tablets dominate the field.... The post 3 Examples of Multiparticulates Enabling Performance a Matrix Tablet Can’t appeared first on Recro.
Show more

Recro Gainesville Frequently Asked Questions

  • When was Recro Gainesville founded?

    Recro Gainesville was founded in 2006.

  • Who are Recro Gainesville key executives?

    Recro Gainesville's key executives are Wayne B. Weisman, David Smithwick and Ryan D. Lake.

  • How many employees does Recro Gainesville have?

    Recro Gainesville has 213 employees.

  • What is Recro Gainesville revenue?

    Latest Recro Gainesville annual revenue is $66.5 m.

  • What is Recro Gainesville revenue per employee?

    Latest Recro Gainesville revenue per employee is $312.2 k.

  • Who are Recro Gainesville competitors?

    Competitors of Recro Gainesville include Skyepharma, Circassia and Array BioPharma.

  • Where is Recro Gainesville headquarters?

    Recro Gainesville headquarters is located at 1300 Gould Dr, Gainesville.

  • Where are Recro Gainesville offices?

    Recro Gainesville has an office in Gainesville.

  • How many offices does Recro Gainesville have?

    Recro Gainesville has 2 offices.